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ABSTRACT
Gastrectomy with lymph node dissection remains the gold standard for curative treatment 
of gastric cancer. Dissection of splenic hilar lymph nodes has been included as a part of D2 
lymph node dissection for proximal gastric cancer. Previously, pancreatico-splenectomy has 
been performed for dissecting splenic hilar lymph nodes, followed by pancreas-preserving 
splenectomy and spleen-preserving lymphadenectomy. However, the necessity of routine 
splenectomy or splenic hilar lymph node dissection has been under debate due to the 
increased morbidity caused by splenectomy and the poor prognostic feature of splenic hilar 
lymph node metastasis. In contrast, the relatively high incidence of splenic hilar lymph node 
metastasis, survival advantage, and therapeutic value of splenic hilar lymph node dissection 
in some patient subgroups, as well as the effective use of novel technologies, still supports 
the necessity and applicability of splenic hilar lymph node dissection. In this review, we 
aimed to evaluate the need for splenic hilar lymph node dissection and suggest the subgroup 
of patients with favorable outcomes.
Keywords: Stomach neoplasms; Splenectomy; Spleen preservation; Lymph node dissection; 
Prognosis
INTRODUCTION
Surgical resection of the primary tumor with its lymphatics remains the gold standard for 
curative treatment of gastric adenocarcinoma. Earlier studies aiming to improve prognosis 
in gastric cancer patients have investigated the lymphatic flow by using activated carbon 
particles or India ink injection [1-4]. The possible lymphatic spread of the tumor was 
determined with the lymphangiogram results, incidence of lymph node metastasis, and 
potential survival benefit of the systematic dissection of the lymphatic flow; moreover, radical 
surgery for gastric cancer has been standardized based on these data.
Comprehensive investigations have demonstrated that the stomach has a sophisticated lymphatic 
flow, and gastric tumors follow various spreading patterns according to the tumor location or 
biology [3-6]. The lymphatic flow of upper body tumors, specifically those located along the 
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greater curvature, is drained to splenic hilar lymph nodes via the left gastroepiploic artery, short 
gastric artery, celiac artery, and posterior gastric artery [4,7]. Therefore, splenic hilar lymph 
nodes, which are also classified as number 10 lymph nodes, were defined as one of the regional 
lymph node groups (N2 group) of gastric cancer (except for lower, lower/middle tumors, which 
are classified as N3 group) [4,8]. In a study that analyzed the lymph node metastasis pattern in 
1,931 gastric cancer patients, the incidence of splenic hilar lymph node metastasis was 9%, with 
the 5-year survival rate of 12% [9]. This study also confirmed that the incidence of splenic hilar 
lymph node metastasis for proximal tumors located at the greater curvature is substantially 
high (32%), whereas that of the tumors along the lesser curvature or on the anterior/posterior 
walls is only up to 6%. Okajima and Isozaki [10] reported that the incidence of the splenic hilar 
lymph node metastasis according to the location of gastric cancer was 26.7%, 15.5%, and 1.9% 
for tumors located in whole stomach, upper body and mid body, respectively; however, no 
metastases were found in the splenic hilar lymph nodes with cancer of the lower third part of the 
stomach. In this context, total gastrectomy with splenectomy for dissecting splenic hilar lymph 
nodes was accepted as a part of curative gastrectomy for proximal gastric cancer [11].
THE INCIDENCE AND RISK FACTORS FOR SPLENIC 
HILAR LYMPH NODES METASTASIS
Following the adoption of splenic hilar lymph node dissection as a part of D2 lymph node 
dissection for proximal gastric cancer, the incidence of splenic hilar lymph node metastasis 
in gastric cancer has been published repeatedly. This incidence in various series, and 
metastasis rates according to the cross-sectional tumor location, Borrmann classification, 
depth of invasion, and pathological stage are summarized in Tables 1–3 [7,12-26]. In these 
series, the incidence of splenic hilar lymph node metastasis was reported to be 8.1%–27.9%, 
and 571 (11.7%) of the 4,900 included patients presented this metastasis. The incidence 
was higher in majority of the studies for tumors located at a greater curvature or encircling 
tumors, Borrmann III–IV class, deeper T stage, and advanced pathological stage. Additional 
clinical factors including younger age, female sex, increased tumor size, poorly differentiated 
or undifferentiated tumors, advanced N stage, presence of lymphovascular invasion, and 
presence of distant metastasis were also identified as risk factors for the splenic hilar lymph 
node metastasis [7,14-18,20,21,25].
In a study by Sasada et al. [7], splenic hilar lymph node metastasis was detected in 31 (15.4%) 
of 201 patients who underwent total gastrectomy and splenectomy for proximal gastric 
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Table 1. The incidence of #10LN according to the cross-sectional tumor location
Author Year Country No. of patients with #10LN 




GC LC AW PW Encircling
Mönig et al. [12] 2001 Germany 11/112 9.8% 37.5% 1.5% 0 0 13.3%
Sasada et al. [7] 2009 Japan 31/201 15.4% 38.5% 2.6% 5.3% 27.8% 22.8%
Shin et al. [14] 2009 Korea 41/319 12.9% 15.6% 9.7% 20.8% 12.0% 23.1%
Aoyagi et al. [15] 2010 Japan 20/191 10.5% 38.1% 0 6.3% 8.6% 17.4%
Kosuga et al. [16] 2011 Japan 30/280 10.7% 19.4% 7.2% 16.2%
Chen et al. [18] 2014 China 18/205 8.8% 18.2% 3.8% 0 13.3% 13.3%
Sun et al. [20] 2015 China 16/150 10.7% 17.8% 4.1% 10.7%
Watanabe et al. [22] 2016 Japan 39/421 9.3% 15.9% 6.2%
Son et al. [23] 2017 Korea 87/602 14.5% 28.8% 9.7% 15.6% 12.3% 45.0%
Jeong et al. [25] 2019 Korea 63/665 9.5% 19.4% 3.5% 8.1% 7.4% 25.7%
Yura et al. [26] 2019 Japan 48/593 8.1% 15.1% 4.2%
#10LN = number 10 lymph nodes; GC = greater curvature; LC = lesser curvature; AW = anterior wall; PW = posterior wall.
cancer. In multivariate analysis of their study, age was the only predictive factor, whereas the 
presence of distant metastasis, tumor size, differentiation, and macroscopic type were not. 
The most important finding of their study was the relationship between the frequency of 
lymph node metastasis and the splenic hilum, cross-sectional tumor location, and T stage. 
Splenic hilar lymph node metastasis was more common in patients with tumor located at 
the greater curvature (38.5%), posterior wall (27.8%), encircling involvement (22.8%), and 
this incidence increased with elevation in the T stage (27.2% for serosa-positive tumors). No 
splenic hilar lymph node metastasis was observed for patients with serosa-negative tumors 
located at the lesser curvature and anterior wall.
Aoyagi et al. reported that cross-sectional tumor location and pathological stage were 
associated with splenic hilar lymph node metastasis. In contrast, age, T stage, N stage, and 
the number of lymph node metastasis were not [15]. In their study, the incidence of splenic 
hilar lymph node metastasis was 38.1% (8 of 21 patients) for the greater curvature tumors and 
17.4% (8 of 46 patients) for encircling tumors. No splenic hilar lymph node metastasis was 
observed in patients with lesser curvature tumors (none of 73 patients). Splenic hilar lymph 
node metastasis was not observed in stage-I tumor patients (none of 25 patients); however, 
it was observed in 34.1% (14 of 41 patients) stage-IV patients. The authors also demonstrated 
the correlation between positivity in #4sa, #4sb, or #11 lymph nodes and the splenic hilar 
lymph node metastasis.
One of the highest incidences for splenic hilar lymph node metastasis was observed in a study, 
which enrolled 265 patients subjected to gastrectomy combined with splenectomy (curative or 
palliative intent), of which 74 (27.9%) patients had splenic hilar lymph node metastasis (23.5% 
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Table 2. The incidence of #10LN according to the Borrmann classification
Author Year Country No. of patients with #10LN  




I II III IV
Mönig et al. [12] 2001 Germany 11/112 9.8% 0 0 1.8% 52.6%
Shin et al. [14] 2009 Korea 41/319 12.9% 11.1% 7.5% 12.2% 34.1%
Aoyagi et al. [15] 2010 Japan 20/191 10.5% 16.7% 4.3% 12.7% 14.3%
Kosuga et al. [16] 2011 Japan 30/280 10.7% 5.3% 26.4%
Zhu et al. [17] 2012 China 74/265 27.9% 14.9% 32.3%
Chen et al. [18] 2014 China 18/205 8.8% 0 10.5% 3.8% 21.7%
Watanabe et al. [22] 2016 Japan 39/421 9.3% 17.1% 14.2%
Son et al. [23] 2017 Korea 87/602 14.5% 10.5% 6.5% 13.1% 24.5%
#10LN = number 10 lymph nodes.
Table 3. The incidence of #10LN according to the depth of invasion and stage
Author Year Country No. of patients with 
#10LN metastasis/




Depth of invasion Stage
M/SM MP SS SE 1 2 3 4
Mönig et al. [12] 2001 Germany 11/112 9.8% 0 0 9.1% 35.7%
Ooki et al. [13] 2008 Japan 18/196 9.2% 2.4% 4.3% 8.5% 18.4%
Sasada et al. [7] 2009 Japan 31/201 15.4% 0 5.3% 6.5% 27.2%
Shin et al. [14] 2009 Korea 41/319 12.9% 0 0 9.7% 22.2% 0 4.5% 9.5% 43.8%
Aoyagi et al. [15] 2010 Japan 20/191 10.5% 9.1% 0 10.5% 12.9% 0 2.5% 6.3% 34.1%
Kosuga et al. [16] 2011 Japan 30/280 10.7% 0 3.2% 11.3% 13.4%
Zhu et al. [17] 2012 China 74/265 27.9% 0 7.7% 17.8% 32.0%
Chen et al. [18] 2014 China 18/205 8.8% 8.3% 0 4.5% 10.6% 0 2.9% 8.5% 23.5%
Sun et al. [20] 2015 China 16/150 10.7% 0 1.3% 14.3% 34.8%
Watanabe et al. [22] 2016 Japan 39/421 9.3% 15.0% 16.7%
Son et al. [23] 2017 Korea 87/602 14.5% 0 3.1% 4.7% 19.2% 0 2.1% 25.1%
Jeong et al. [25] 2019 Korea 63/665 9.5% 0 0 5.6% 19.7% 0 0 13.5% 38.3%
#10LN = number 10 lymph nodes; M = mucosa; SM = submucosa; MP = muscularis propria; SS = subserosa; SE = serosa.
for patients who underwent R0 resection) [17]. Younger age, Borrmann III–IV lesions, Lauren 
diffuse-type histology, lymphovascular invasion, T stage, N stage, presence of nonregional 
lymph node metastasis, and peritoneal cytology positivity as significant risk factors correlated 
with splenic hilar lymph node metastasis. Among these, T stage, N stage, and the presence of 
distant lymph node metastasis were independent risk factors. While no splenic hilar lymph 
node metastasis was observed in early gastric cancer, 28.9% (41 of 142 patients) of serosa 
positive tumors and 39.3% (24 of 61 patients) of tumors with adjacent organ invasions had 
splenic hilar lymph node metastasis. Moreover, splenic hilar lymph node metastasis was 
identified in 49.3% (33 of 67 patients) of patients with 7–15 positive lymph nodes, 82.4% (28 
of 34 patients) of patients with >15 positive lymph nodes, and 72.8% (16 of 22 patients) with 
distant lymph node (#13, #14a, and those beyond #15) metastasis.
In another study, the risk factors related to splenic hilar lymph node metastasis in patients 
with advanced cancer, T stage, differentiation, tumor size, cross-sectional location, and 
Bormann type were associated with the splenic hilar lymph node metastasis; however, 
multivariate analysis demonstrated that only T stage and tumor size act as the independent 
factors [20]. Incidences of splenic hilar lymph node metastasis were 1.3%, 14.3%, and 34.8% 
for T2, T3, and T4 tumors, respectively. Splenic hilar lymph node metastasis was observed in 
only 3 of 89 (3.4%) patients with tumors smaller than 5 cm and in 13 of 61 (21.3%) patients 
with larger tumors. In this study, they highlighted the importance of preoperative risk 
prediction for developing a rational surgical strategy for advanced gastric cancer.
In 2017, Hong et al. [21] designed a modeling system to predict the risk of splenic hilar lymph 
node metastasis for advanced upper gastric cancer. Tumor size, cT stage, and cN stage are 
considered as independent risk factors for patients undergoing curative gastrectomy with 
spleen-preserving splenic hilar lymph node dissection excluding stump cancer, tumors 
invading the adjacent organs, and M1 disease. To create a scoring system, patients were 
divided into three groups (low, intermediate, and high risk) by using the following factors: 
2 points for ≥5 cm tumor size, 1 point for serosal involvement, and 1 point for lymph node 
positivity. The incidences of splenic hilar lymph node metastasis were 2.8%, 13.9%, and 
34.9%, for low, intermediate, and high-risk groups, respectively. Moreover, an algorithm 
based on the scoring system for splenic hilar lymph node management was proposed.
SURVIVAL BENEFIT OF NUMBER 10 LYMPH NODE 
DISSECTION
Several studies have compared the survival outcomes of patients with and without splenic 
hilar lymph node metastasis. Moreover, the therapeutic value of splenic hilar lymph node 
dissection was evaluated as a form of the therapeutic index (TI), which was calculated by 
multiplying the splenic hilar lymph node metastasis incidence by the 5-year overall survival in 
patients suffering from this disorder [27].
In patients who underwent total gastrectomy plus splenectomy, 5-year survival rates were 
reported as 5.4%–26% for patients with splenic hilar lymph node metastasis, and majority of 
the studies have reported poor outcomes in patients with splenic hilar lymph node metastasis 
compared to the patients without it [7,14,17,25,28]. Subsequent studies have also investigated 
the efficacy of dissecting splenic hilar lymph nodes in subgroups, not all patients. The 5-year 
survival rate has been reported up to 51.3% in the subgroups. No survival difference was 
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found in few studies, whereas some studies argued the potential benefits of splenic hilar 
lymph node dissection in the subgroups.
In Aoyagi's study [15], the presence of splenic hilar lymph node metastasis did not reveal 
survival difference for stages IIIB and IV patients. In a study by Kosuga et al. [16], no 
significant difference was observed in 5-year survival between patients with splenic hilar 
lymph node metastasis and those without it (51.3% and 42.1%, respectively). The overall TI 
of the projected benefits from splenic hilar lymph node dissection was 5.49 (incidence was 
10.7%). In subgroups of greater curvature and Borrmann-IV cancers, therapeutic indices were 
19.4 and 12.9, respectively; however, encircling tumors (TI=1.62) and tumors invading the 
adjacent organs (TI=0) demonstrated quite low therapeutic value from splenic hilar lymph 
node dissection.
We recently investigated the impact of splenic hilar lymph node metastasis on prognosis 
in patients with advanced gastric cancer [23]. To this end, we analyzed 602 patients who 
underwent total gastrectomy with D2 lymph node dissection. We evaluated the subgroups 
of patients with metastasis to the splenic hilar lymph node, patients with metastasis to 
extraperigastric stations (#8a, #9, #11, or #12a), and patients with distant metastasis. 5-year 
overall survival in patients with splenic hilar lymph node metastasis was 24.1% (54.8% for 
patients without splenic hilar lymph node metastasis) and the TI for splenic hilar lymph 
node was 3.5; however, no significant differences were observed in the overall survival 
between patients with splenic hilar lymph node metastasis and those with metastasis to 
extraperigastric stations. Overall survival in patients with splenic hilar lymph node metastasis 
was better than that of patients with splenic hilar lymph node plus distant metastasis, and 
that of patients with distant metastasis but without splenic hilar lymph node metastasis. 
Moreover, the peritoneum was the most common recurrence site, despite involvement of any 
extraperigastric lymph nodes. This study revealed that dissection of splenic hilar lymph node 
provides a similar prognosis to that achieved with the dissection of extraperigastric lymph 
nodes in patients who underwent total gastrectomy for advanced gastric cancer.
Three studies from Japan investigated the value of splenic hilar lymph node dissection in 
proximal gastric cancer by dividing the patients into two groups as a greater curvature group 
(with tumors involving the greater curvature) and a nongreater curvature group (without 
tumors involving the greater curvature) [22,24,26]. In the first study by Watanabe et al. [22], 
the incidence of splenic hilar lymph node metastasis in the greater curvature group was 
15.9% (6.2% for nongreater curvature group, P=0.032). In the greater curvature group, 5-year 
overall survival rates with and without splenic hilar lymph node metastasis were 35.4% and 
43.1%, respectively (P=0.135), and these rates in the nongreater curvature group were 32.8% 
and 66.5%, respectively (P<0.001). The TI of splenic hilar lymph node was 5.6 in the greater 
curvature group and 2.0 in the nongreater curvature group. The greater curvature group 
was further analyzed in the study, and patients aged <65 years (TI=8.2), with Borrmann-IV 
(TI=7.1), and with <T4 stage (TI=10.0) demonstrated relatively higher therapeutic indices.
Maezawa et al. [24] investigated the efficacy of splenic hilar lymph node dissection by 
comparing it to that of the other regional nodes in locally advanced proximal gastric cancer 
invading the greater curvature. The incidence of splenic hilar lymph node metastasis, 5-year 
overall survival, and TI were 13.4%, 30%, and 4.02%, respectively. The most important 
finding of the study was the substantially higher TI of splenic hilar lymph node than those 
of #8a, #11p, and #11d. The authors suggest that the presence of splenic hilar lymph node is 
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higher than that of the #11 lymph nodes, and they recommended the removal of the splenic 
hilar lymph nodes as a part of D2 dissection for proximal gastric cancer detected in the 
greater curvature.
A recent study evaluated the efficacy of splenic hilar lymph node dissection for advanced 
gastric cancer invading the greater curvature [26,29]. No statistically significant difference 
was observed in 5-year survival for the patients with and without splenic hilar lymph node 
metastasis in the greater curvature group, whereas significant difference was observed in 
the nongreater curvature group. The TI of the splenic hilar lymph node station was 7.1 in the 
greater curvature group, and higher than those of the essential components of D2 dissection, 
including #5, #6, #8a, #9, #11p, #11d, and #12.
In addition to the observational studies, randomized comparative studies evaluating the 
impact of splenic hilar lymph node dissection were also published. The first randomized 
study in English literature was the Chilean study published in 2002 [30]. Herein, the authors 
compared total gastrectomy versus total gastrectomy with pancreas-preserving splenectomy 
in patients with gastric cancer. Patients with macroscopic metastasis at the splenic hilum 
and macroscopic findings of spleen invasion have not been included. Splenic hilar lymph 
node metastasis was detected in 8 (9%) of 90 patients in total gastrectomy plus splenectomy 
group. The 5-year survival rates were not statistically different between groups (36% in total 
gastrectomy group and 42% in total gastrectomy plus splenectomy group). The authors 
concluded that splenectomy does not influence the survival after total gastrectomy in early 
stages and may be performed only in selected patients with an advanced-stage disease.
The most systematic randomized study to evaluate splenectomy in total gastrectomy for 
proximal gastric cancer was published by the Stomach Cancer Study Group of the Japan 
Clinical Oncology Group in 2017 (JCOG0110) [31]. In this noninferiority trial, 505 patients 
from 36 institutions were randomized to splenectomy or spleen preservation groups. The 
5-year overall survival rates were 75.1% and 76.4% for the splenectomy and the spleen 
preservation group, respectively. Statistically significant noninferiority of spleen preservation 
was presented, and the authors concluded that splenectomy should be avoided; however, 
certain crucial points were highlighted in the study design. Patients with the tumor invading 
the greater curvature, those with gastric remnant cancer, those with Borrmann-IV, and 
patients with gross lymph node metastasis at splenic hilum were excluded from the study, 
that is, patients at high risk for splenic hilar lymph node metastasis were eliminated. 
Moreover, only advanced cancer was supposed to be included; 14.1% of the included patients 
had pathological T1 tumors. Therefore, the incidence of splenic hilar lymph node metastasis 
was quite low (2.4%) in the splenectomy group, compared to the previous studies [32,33]. 
In 58 of 254 patients in the spleen preservation group, splenic hilar lymph node dissection 
or sampling was performed without splenectomy. Considering the strict eligibility study 
criteria, the results should not be extrapolated to all gastric cancer patients, and certain 
questions still need to be answered.
FEASIBILITY OF SPLENIC HILAR LYMPH NODE 
DISSECTION WITHOUT SPLENECTOMY
Removal of the spleen, which is a part of the immune system, has been questioned due to its 
possible effects on short- and long-term outcomes. Although several surgeons have routinely 
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performed splenectomy for the removal of splenic hilar lymph nodes, it is possible to remove 
the same group of lymph nodes by preserving the spleen and splenic vessels. A randomized 
study comparing spleen-preserving splenic hilar lymph node dissection and splenectomy 
for proximal gastric cancer demonstrated that a similar number of lymph nodes could be 
removed with both approaches, and that no survival advantage of splenectomy exists over 
spleen-preserving dissection [34]. In subsequent studies, spleen-preserving dissection 
was commonly performed with open or laparoscopic approach [35-38]. Interim report of 
a randomized trial comparing the laparoscopic and open spleen preserving splenic hilar 
lymph node dissection demonstrated that operative time, number of harvested lymph nodes 
including splenic hilar lymph node, time taken for splenic hilar lymph node dissection, 
as well as the complication rates are comparable between the groups [39]. In addition to 
the successful applications of laparoscopic splenic hilar lymph node dissection, robotic 
surgery is known to be a feasible and safe approach for spleen-preserving splenic hilar lymph 
node dissection [40,41]. Image-guided surgery with the assistance of 3D simulation and 
fluorescent lymphography–guided lymph node dissection are also tools that assist surgeons 
regarding the appropriate anatomy of the splenic vessels before surgery and in identifying all 
necessary lymph nodes [42-45].
SUMMARY
Several factors determine the direction and timing of the lymphatic spread of gastric cancer. 
The splenic hilar lymph node group is one of the essential targets in the surgical treatment 
of proximal gastric cancer, and published studies have reported various incidences of splenic 
hilar metastasis and survival rates for patients with splenic hilar lymph node metastasis. 
The overall incidence of splenic hilar lymph node metastasis was reported up to 27.9% in 
gastric cancer, and a correlation was observed between the risk of splenic hilar lymph node 
metastasis and several clinicopathological factors including age, cross-sectional tumor 
location, tumor size, T stage, N stage, and pathological stage. All these factors except for 
the tumor location are parts of advanced or systemic disease and they mostly reflect poor 
prognosis for gastric cancer patients. Thus, studies exploring long-term outcomes of splenic 
hilar lymph node dissection failed to present a survival benefit. It is rational to use a cross-
sectional tumor location as the best candidate variable in selecting patients who would 
benefit from the splenic hilar lymph node dissection. The recent randomized trial, which 
has a strict eligibility criteria, concluded that routine splenic hilar lymph node dissection is 
not required in all patients requiring total gastrectomy; however, no convincing evidence is 
available to ignore the benefit of splenic hilar lymph node dissection in patients with a high 
risk of splenic hilum lymph node metastasis.
CONCLUSIONS
The potential benefit of splenic hilar lymph node dissection becomes more pronounced 
when demonstrated by the relatively higher TI, specifically in tumors involving greater 
curvature of the proximal stomach and conceivably for Borrmann type IV tumors. Therefore, 
the dissection of splenic hilar lymph node should be considered and allowed to be a part of 
curative surgery in selected patient groups, if R0 resection is intended.
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